Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institute of Hematology & Blood Diseases Hospital, China
Enrolled patients will receive EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) ±R /DHAP(cisplatin, cytarabine and dexamethasone) ±R alternating chemotherapy. If a partial remission or better response achieves, patients will be recommended to receive autologous stem cell transplantation as consideration therapy or another two cycles EDOCH ±R /DHAP±R chemotherapy (based on patient's choice). Patients with less than partial remission (PR) response will quit this study. After treatments finished, maintenance therapy with rituximab or thalidomide plus prednisone will be given less than two years. The determination of maintenance regimens is dependent on patients choices.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age≤65 years
diagnosis with mantle cell lymphoma
Ann Arbor stage II,III or IV
ECOG≤1 or if ECOG≥2 but recover after pretreatment.
You may not be if
with centre neural system involvement
serious complications such as uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician
HIV positive or active HBV infection or other uncontrolled systematic infection
clinical central nervous dysfunction
serious surgery within 30 days
pregnancy or baby nursing period or un-contracepted child bearing period woman.